title: The recent JALSG study for newly diagnosed patients with acute promyelocytic leukemia (APL).
abstract: Based on the prognostic factors obtained from our previous APL92 study, in the JALSG APL97 study, we intensified chemotherapy for patients with leukocyte counts > or = 3,000/microL and > or = 10,000/microL, also intensified consolidation chemotherapy, and then tested whether further chemotherapy is required in patients with negative RT-PCR for PML/RARalpha after the completion of consolidation therapy. Of 256 presently evaluable patients, 244 (95%) achieved CR. Predicted 5-year EFS is 67% and predicted 5-year overall survival 84%.
authors.affiliation: Aichi Cancer Center, Nagoya, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Ohno
authors.forename: N
authors.initials: N
authors.lastname: Asou
mesh_terms: D000328:Adult; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D014212:Tretinoin